A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
Definition, mechanism, and the clinical reality of this diagnosis at end of life. What the hospice team needs to understand on day one.
Systemic amyloidosis is a group of diseases in which misfolded proteins deposit as insoluble amyloid fibrils in organs throughout the body, progressively destroying organ function. The two most clinically significant types are AL (light chain) amyloidosis — caused by a monoclonal plasma cell clone producing amyloidogenic immunoglobulin light chains — and ATTR (transthyretin) amyloidosis — caused by misfolded transthyretin protein from either aging (wild-type ATTR) or inherited TTR gene mutations (hereditary ATTR). The amyloid fibrils deposit in the heart, kidneys, nerves, liver, and soft tissues, producing a clinical picture that looks like heart failure, neuropathy, and kidney disease simultaneously — but responds to none of the standard treatments for those conditions.[1]
The hospice-eligible amyloidosis patient is typically arriving with advanced cardiac amyloidosis (the leading cause of death in both AL and ATTR), often combined with peripheral and autonomic neuropathy, nephrotic syndrome or renal failure, and sometimes macroglossia or soft tissue deposits. The amyloid cardiomyopathy produces a restrictive physiology with preserved ejection fraction — the heart walls are stiff and thickened from amyloid infiltration, the ventricle cannot relax and fill properly, and the stroke volume is fixed. This is fundamentally different from dilated cardiomyopathy, and the medications that are standard heart failure therapy — digoxin, calcium channel blockers, ACE inhibitors, beta-blockers — are either directly harmful or poorly tolerated in amyloid cardiomyopathy.[12]
The hospice clinician must understand three critical facts on day one: (1) the cardiac medications on the patient's list may be causing active harm and must be reviewed immediately; (2) the autonomic neuropathy means that every position change is a syncope risk; and (3) this patient and family have endured a diagnostic odyssey of 2–3 years during which the disease progressed without specific treatment, and the grief about that delay is as real as the organ failure it caused.[4]
Amyloid cardiomyopathy is the opposite of standard heart failure. The ejection fraction is preserved or only mildly reduced, but the heart is failing because it cannot fill — not because it cannot pump. The medications designed to help a weak, dilated heart (digoxin, beta-blockers, ACEi) make a stiff, restrictive heart worse. The single most important clinical act at hospice enrollment is reviewing the cardiac medication list and removing the medications that are causing harm. This is the thing that defines every visit with this diagnosis.
Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Your person's amyloidosis was diagnosed through a biopsy — a small tissue sample that showed protein deposits under a special microscope. The type of amyloidosis was identified through specialized laboratory testing. All of this diagnostic work is already complete. At hospice enrollment, the focus shifts entirely to comfort — no more biopsies, no more scans for diagnosis. The medical team uses the information already gathered to guide the best possible comfort care.
Próximamente en español.
Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
Amyloidosis is not caused by anything your loved one did or didn't do. AL amyloidosis occurs because a small group of cells in the bone marrow began producing an abnormal protein — this is not related to diet, lifestyle, or environmental exposure. ATTR amyloidosis occurs either from aging (wild-type) or from an inherited gene variant that has been passed through families for generations. If your person has hereditary ATTR amyloidosis, the hospice team can help arrange genetic counseling for family members who may want to know if they carry the same gene — not to cause worry, but because early detection and treatment can now change outcomes significantly.
The Val122Ile TTR variant is carried by approximately 3–4% of Black Americans. For decades, the heart failure it causes was attributed to hypertensive cardiomyopathy or idiopathic HFPEF, contributing to documented racial disparities in heart failure outcomes. The recognition and correct diagnosis of Val122Ile-associated amyloid cardiomyopathy is one of the most significant health equity findings in cardiovascular medicine. At hospice enrollment, if the patient is Black and has ATTR cardiomyopathy, ensure the hereditary variant has been assessed. Genetic counseling for family members is a clinical obligation — not an optional referral.[3][36]
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Disease-modifying therapy in amyloidosis — the clinical landscape the hospice clinician must understand. Unlike most hospice diagnoses where disease-directed treatment is clearly behind the patient, amyloidosis presents a more nuanced treatment-to-comfort transition. AL amyloidosis is a hematological malignancy whose treatment targets the plasma cell clone; ATTR amyloidosis has targeted therapies (tafamidis, patisiran) that stabilize or reduce TTR protein. The hospice clinician must understand what treatments the patient received, why they stopped, and which medications may appropriately continue even at hospice enrollment.[17]
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
Immediate medication safety review at enrollment is the single most important clinical act in amyloidosis hospice. Before any other assessment, the cardiac medication list must be reviewed for the medications that cause harm in amyloid cardiomyopathy. This review — and the communication with the prescribing cardiologist — is a first-visit obligation that prevents ongoing iatrogenic injury.[12]
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Knowing which medications and interventions cause harm in amyloidosis is as clinically important as knowing which ones help. The medications listed below are standard heart failure therapy in dilated cardiomyopathy — and directly harmful in amyloid cardiomyopathy. The hospice clinician who identifies and removes these medications has made one of the most impactful clinical safety contributions in all of hospice medicine.[12]
The false equivalence between "standard heart failure management" and "good clinical care" is the most dangerous assumption in amyloidosis hospice. The cardiologist who prescribed digoxin and lisinopril for a patient labeled "HFPEF" was practicing correct medicine for the wrong diagnosis. The hospice clinician who recognizes amyloid cardiomyopathy and contacts the cardiologist about these medications is not overstepping — they are providing critical clinical safety information that may not have been recognized. Approach this communication with respect and clinical precision: "I'm reviewing the medication list for a patient with amyloid cardiomyopathy and want to confirm whether digoxin and the ACE inhibitor should continue given the restrictive physiology."
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.
Systemic amyloidosis creates a supplement safety landscape defined by three simultaneous concerns: (1) cardiac medication interactions — the amyloid cardiomyopathy patient is on carefully titrated furosemide and possibly amiodarone; electrolyte-affecting supplements interact with both; (2) amyloid fibril interaction biology — certain flavonoids (EGCG, curcumin) have laboratory amyloid fibril disruption activity that has generated patient interest but lacks clinical trial evidence at OTC doses; (3) the rare disease information vacuum — patients encounter a mix of legitimate emerging research and predatory marketing. No supplement has been shown to reduce organ amyloid burden or halt amyloidosis progression in human clinical trials at OTC doses.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Melatonin | Grade C | 1–5 mg PO at bedtime | Sleep disruption from neuropathic pain and cardiac dyspnea. Safe and well-tolerated. May reduce nighttime neuropathic pain perception through anti-inflammatory mechanisms. | Minimal interactions at this dose. Safe with furosemide, gabapentin, and opioids. May cause morning grogginess — start at 1 mg. |
| EGCG (Green Tea Extract) | Grade C | 400–800 mg standardized extract daily | Laboratory evidence of amyloid fibril disruption. Mayo Clinic trials explored EGCG for AL amyloidosis cardiac involvement (NCT02015312). The evidence is preliminary — no completed RCT demonstrates clinical organ improvement at OTC doses. | ⚠ Hepatotoxicity risk at high doses. CYP interactions may affect medication metabolism. May interfere with bortezomib efficacy (if still receiving). Caffeine content may worsen tachyarrhythmias. Discuss with hematologist before use. NOT a substitute for anti-amyloid therapy. |
| Curcumin (Turmeric Extract) | Grade C | 500–1000 mg standardized curcumin daily | In vitro evidence of amyloid fibril disruption and anti-inflammatory properties. Patients frequently self-prescribe based on online amyloidosis community recommendations. | ⚠ Antiplatelet activity — risk of bleeding in patients with factor X deficiency (AL amyloidosis). GI irritation may worsen gastroparesis. Bioavailability extremely low without piperine. Not harmful at standard doses in most patients but benefits are unproven. |
| Magnesium Glycinate | Grade C | 200–400 mg elemental Mg daily | Furosemide-induced hypomagnesemia contributes to muscle cramps, fatigue, and may worsen arrhythmias. Repletion of furosemide-induced losses. | Monitor levels if renal function impaired (amyloid nephropathy). Reduce dose if GFR <30. May cause diarrhea — use glycinate form (best tolerated). Interactions with amiodarone QT effects — monitor. |
| Coenzyme Q10 (CoQ10) | Grade D | 100–200 mg daily | Theoretical mitochondrial support for cardiomyocytes. No amyloidosis-specific evidence. Used widely in heart failure patients — safety profile acceptable. | May reduce warfarin efficacy (if anticoagulated for AF). No known harmful interactions with furosemide or amiodarone. Expensive; benefit uncertain. |
| Alpha-Lipoic Acid | Grade D | 300–600 mg daily | Antioxidant with some evidence in diabetic neuropathy pain. May provide modest benefit for amyloid neuropathic pain as adjunct to gabapentin. | May lower blood glucose — monitor in diabetic patients. Generally safe. GI upset possible. Limited evidence base for amyloid-specific neuropathy. |
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.
The systemic amyloidosis timeline is distinguished by two features: the diagnostic odyssey that precedes the correct diagnosis by 2–3 years (during which organ damage accumulates without specific treatment), and the variation by amyloid type and organ involvement — AL amyloidosis with cardiac involvement may follow a 3–6 month trajectory while hATTR Val30Met neuropathy may span 10–15 years. The hospice clinician must understand which type and which organs dominate for the specific patient to communicate prognosis accurately.[5]
Symptom-targeted pharmacology for this diagnosis. What to have in the comfort kit, what to titrate first, and what the evidence supports.
(1) REMOVE DIGOXIN — contraindicated in amyloid cardiomyopathy from myocardial fibril binding; remove from the active medication list; contact the cardiologist; document the contraindication as prominently as morphine in ESRD. (2) REMOVE DILTIAZEM AND VERAPAMIL — same fibril binding mechanism; absolutely contraindicated. (3) REASSESS ACE INHIBITORS, ARBs, AND BETA-BLOCKERS — evaluate blood pressure and clinical hemodynamics; if systolic BP <100 mmHg, these medications are causing hypotension; contact the cardiologist for reassessment.
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Furosemide | Loop diuretic / Volume overload | 20–80 mg PO daily | Primary safe diuretic for amyloid cardiomyopathy. Titrate to symptom comfort — edema relief, dyspnea relief. Weigh daily; monitor creatinine. SQ furosemide 20–80 mg if oral absorption impaired. The window between overload and depletion is narrow in restrictive physiology.[15] |
| Spironolactone | Aldosterone antagonist / Volume adjunct | 25–50 mg PO daily | Safe in amyloid cardiomyopathy. Potassium-sparing — monitor K+ closely, especially with declining renal function. Do not combine with ACEi/ARB if already hyperkalemic.[15] |
| Gabapentin | Anticonvulsant / Neuropathic pain | 100–300 mg PO QHS → 300 mg TID | First-line for amyloid neuropathic pain. Start low at bedtime; titrate over 1–2 weeks. Dose-reduce in renal impairment (GFR <30: max 300 mg/day). Drowsiness at initiation is common — reassure patient it improves.[33] |
| Duloxetine | SNRI / Neuropathic pain adjunct | 30 mg PO daily → 60 mg daily | Synergistic with gabapentin for neuropathic pain. ⚠ May worsen orthostatic hypotension — monitor BP closely after initiation. Contraindicated in severe hepatic impairment (liver amyloidosis). Taper if discontinuing.[33] |
| Midodrine | Alpha-1 agonist / Orthostatic hypotension | 2.5–10 mg PO TID with meals | Preferred over fludrocortisone in amyloid cardiomyopathy (avoids volume expansion). Last dose by 4 PM (supine hypertension risk). Start 2.5 mg TID; titrate to effect. Monitor supine BP.[31] |
| Droxidopa | Norepinephrine precursor / Severe orthostatic hypotension | 100 mg PO TID → titrate to 600 mg TID | FDA-approved for neurogenic orthostatic hypotension. For severe amyloid autonomic neuropathy when midodrine alone is insufficient. Monitor supine hypertension. Expensive — verify insurance coverage.[31] |
| Metoclopramide | Prokinetic / Gastroparesis | 5–10 mg PO 30 min AC + QHS | Improves gastric motility in amyloid gastroparesis. Avoid in complete obstruction. Limit to 12 weeks if possible (tardive dyskinesia). ⚠ Extrapyramidal symptoms — monitor. |
| Amiodarone | Antiarrhythmic / AF rate control | 100–200 mg PO daily | The ONLY safe rate control agent in amyloid cardiomyopathy AF. Low maintenance dose after loading. Monitor thyroid and pulmonary function. ⚠ Do NOT substitute digoxin, diltiazem, or verapamil.[34] |
| Morphine | Opioid / Pain + Dyspnea | 2.5–5 mg PO/SQ q4h PRN | For dyspnea refractory to diuresis, breakthrough neuropathic pain, and comfort at end of life. Start low. If liver amyloidosis impairs hepatic metabolism, use hydromorphone as alternative. Ensure bowel regimen.[44] |
| Ondansetron | 5-HT3 antagonist / Nausea | 4–8 mg PO/SL q8h PRN | For nausea from gastroparesis, medication effects, or uremia. Safe in amyloidosis. May cause constipation — monitor bowel function. ODT (orally disintegrating tablet) for patients with macroglossia/swallowing difficulty. |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Adjunctive for anxiety, dyspnea-associated distress, and anticipatory nausea. Avoid scheduled use unless breakthrough is frequent. Safe in hepatic impairment (no hepatic metabolism — glucuronidation only). |
| Midazolam | Benzodiazepine / Terminal agitation | 2.5–5 mg SQ PRN | Terminal agitation, refractory dyspnea, catastrophic event management. Have drawn and labeled in comfort kit at bedside. CSCI 10–30 mg/24h for refractory terminal symptoms. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. Repositioning and gentle oral suctioning as adjuncts. |
| Haloperidol | Antipsychotic / Delirium + nausea | 0.5–2 mg PO/SQ q4–8h | First-line for terminal delirium. Also effective as antiemetic. Low dose. ⚠ QTc prolongation — use with caution alongside amiodarone; monitor ECG if both prescribed. |
| Mirtazapine | NaSSA / Depression + insomnia + anorexia | 7.5 mg PO QHS | Addresses depression, insomnia, and poor appetite simultaneously. Faster onset than SSRIs in this population. Low dose is more sedating (useful for sleep). Safe in renal impairment. |
Morphine 20 mg/mL concentrate: 2.5–5 mg SQ q2–4h for dyspnea or pain crisis. Midazolam 5 mg/mL: 2.5–5 mg SQ for terminal agitation, refractory dyspnea, or catastrophic arrhythmia event — have drawn and labeled at bedside. Lorazepam 2 mg/mL: 0.5–1 mg SQ for anxiety or dyspnea distress. Glycopyrrolate 0.2 mg/mL: 0.2 mg SQ for terminal secretions. Haloperidol 5 mg/mL: 0.5–1 mg SQ for delirium or nausea. Furosemide 10 mg/mL: 20–40 mg SQ for acute volume overload when oral route is lost. Dark towels: At bedside for potential bleeding event (factor X deficiency in AL amyloidosis).
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.
Systemic amyloidosis produces a psychosocial and spiritual burden that is unique among hospice diagnoses — defined by the diagnostic odyssey grief, the isolation of a rare disease, the multi-organ burden that exceeds the sum of individual organ failures, and the specific health equity dimensions of ATTR amyloidosis in the Black community. The hospice social worker and chaplain are not optional referrals in amyloidosis — they are essential members of the clinical team from enrollment day one.[44]
Your job is not to provide the answers. Your job is to ask the questions that make space for the patient's own answers to emerge — and to connect them with the right people when they need more than you can offer.
The amyloidosis patient who was told for 2–3 years that they had idiopathic heart failure, idiopathic neuropathy, or MGUS "without clinical significance" has experienced a specific form of medical harm. Organs that are now failing were accumulating amyloid during those years without specific treatment. The anger and grief about the diagnostic delay is legitimate and may be profound.[4]
Clinical language: "I know the road to this diagnosis was a long one and that the disease was progressing during the time it took to get here. That is a legitimate grief and it deserves to be named."
The amyloidosis patient is dying from a disease that most of their family, friends, and community have never heard of. There is no breast cancer pink ribbon, no heart disease red dress, no ALS ice bucket for amyloidosis. The social isolation of an unfamiliar diagnosis is real and documented.[44]
The patient with cardiac amyloidosis AND peripheral neuropathy AND autonomic neuropathy AND renal amyloidosis AND gastroparesis AND macroglossia is carrying a burden whose totality exceeds the sum of any single organ's failure. The grief of watching every system fail simultaneously — the heart that cannot pump, the nerves that burn and fail to regulate blood pressure, the kidneys that leak protein, the stomach that cannot process food, the tongue that cannot form words — produces an existential weight that standard depression screening cannot fully capture. Ask: "Of everything this disease has taken from you, what do you miss the most?" This question opens the door to the specific grief of multi-organ loss.[44]
"The amyloidosis patient who says 'I'm tired of fighting' may not be expressing depression or giving up — they may be expressing the rational exhaustion of a person who has been fighting a disease that attacks every organ simultaneously for years without adequate clinical support. Validate the exhaustion before screening for depression."
For Black families affected by Val122Ile ATTR amyloidosis, the psychosocial dimensions include the intersection of a rare disease with documented racial disparities in cardiovascular care. The heart failure that was attributed to hypertension for years may have been amyloid all along. The genetic counseling conversation — "this gene variant runs in families of West African descent; your children and siblings may carry it" — has implications for family relationships, insurance, and identity that extend beyond medicine. The hospice social worker must be prepared for these conversations with cultural competence and sensitivity to the specific historical context of genetic testing in Black communities.[36]
Passive wish for death ("I'm ready to go") is common in amyloidosis — particularly in patients exhausted by multi-organ disease and the diagnostic odyssey. It is not the same as active suicidal ideation. Assessment requires careful distinction: passive wish for death (common, often appropriate in terminal illness), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol). The amyloidosis patient who says "I don't want to do this anymore" may be expressing exhaustion, appropriate readiness, untreated depression, or uncontrolled symptoms — the clinical response depends on which one. Do not avoid the question.
Plain language for families. Share, print, or read aloud at the bedside.
To the family of a person living with amyloidosis: Your person has a disease that affects multiple organs at the same time — the heart, the nerves, the kidneys, and sometimes the tongue and other tissues. It has a name that most people have never heard, and the road to getting that name was probably long and frustrating. You may be carrying anger about the years it took to get the right diagnosis. That anger is valid. What matters now is that your person is getting care focused entirely on their comfort — on managing the symptoms that affect their daily life, on preventing unnecessary suffering, and on making every day as good as it can be. You are the most important part of that care team.
Próximamente en español.
Fainting or loss of consciousness — especially during or after standing; lay the person flat immediately and call. Sudden worsening of breathing difficulty — gasping, unable to speak in full sentences, blue lips. Rapid increase in leg or abdominal swelling — more than normal; especially with breathing difficulty. Chest pain or awareness of rapid/irregular heartbeat — especially new or significantly different from baseline. Significant bleeding — nosebleeds that won't stop, blood in stool, large bruises appearing without injury (factor X deficiency may be present). New confusion, agitation, or unresponsiveness — could be low blood pressure, medication effect, or disease progression. Difficulty swallowing or choking episodes — especially if macroglossia is present. Severe pain not controlled by the current medications — there are always adjustments available. Shocks from the defibrillator (ICD) — if the device has not yet been deactivated and delivers a shock, call immediately.
🙏 Research consistently shows that patients with engaged family caregivers experience better symptom control, less anxiety, and greater comfort at end of life. In amyloidosis — where the disease attacks so many systems simultaneously — your presence and your understanding of the daily management needs are not optional add-ons to clinical care. They are clinical care. The position change protocol you follow, the daily weight you record, the 6 small meals you prepare, the dangerous medication you prevent from being prescribed — these are clinical interventions. You are doing the work that matters most.
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by study design. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.